IRCT20210519051345N32
Recruiting
未知
Bioequivalence study of Famotidine 40 mg tablet compared with innovator product
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Tabriz University of Medical Sciences
- Enrollment
- 24
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •General Health (in terms of Liver, Heart and Kidney)
- •Age (18\-59 years)
Exclusion Criteria
- •History of cardiovascular disease, liver and kidney disease
- •Alcohol and drug addiction
- •History of drug allergy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Bioequivalence study of Famotidine 40 mgIRCT20200623047902N14Sanamed pharma company24
Recruiting
Not Applicable
Bioequivalence study of Famotidine 40 mg tabletIRCT20200105046010N85Tabriz University of Medical Sciences24
Completed
Not Applicable
Bioequivalance study of Famotidine 40 mgIRCT20200513047423N5Fatak chemie pars Pharmacy24
Not yet recruiting
Not Applicable
Bioequivalance study of Famotidine 40 mgSubject: Bioequivalence of Famotidine 40 mg Tablet and Comparison of Pharmacokinetic Parameters with Ratiopham Reference Tablet.IRCT20200513047423N9Iran Daru Pharmaceutical Company24
Recruiting
Not Applicable
Bioequivalence study of famotidine 40 mg tabletIRCT20230222057495N12Ramopharmin Pharmaceutical Company24